DURHAM, NC - Studies indicate that replacing damaged brain cells with those derived from human embryonic stem cells might lead to an effective treatment for Parkinson’s disease. But what has not been determined is the optimal stage during differentiation of the stem cells that the transplantation should take place to gain the best results.
You are here
Press Releases from AlphaMed Press
DURHAM, NC - A study recently published in STEM CELLS Translational Medicine shows smooth muscle and vascular endothelial cells induced from pluripotent stem cells perform similarly to their naturally evolving counterparts under conditions that mimic hardening of the arteries and other blood vessel diseases. The finding opens the door to modeling rare vascular diseases necessary for research, as well as assists in screening new drugs and developing personalized cell-based therapies.
DURHAM, NC - A new study demonstrates how an infusion of stem cells can assist in treating severe cases of aplastic anemia (AA) that do not respond to immunosuppressive therapy (IST) alone. The study, which appears in STEM CELLS Translational Medicine (SCTM), offers hope for patients with this rare disease, which occurs when the bone marrow does not produce enough blood cells to meet the body’s needs.
DURHAM, NC - AlphaMed Press and the Cord Blood Association (CBA) are pleased to announce that STEM CELLS Translational Medicine (SCTM) is now the association’s official journal. With this partnership, SCTM will launch a new journal section dedicated to cord blood research.
“We are delighted to initiate this partnership with the Cord Blood Association,” said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine. “With this new journal section, SCTM further expands the scope of new research reports for our readers – with the potential to accelerate progress in regenerative medicine.”
DURHAM, NC - Currently symptomatic therapies for Parkinson’s Disease (PD) produce unwanted side effects and diminished effectiveness over time. A recent study published in STEM CELLS suggests that human neural stem cell (hNSC) transplantation could help to treat PD by stimulating subventricular zone (SVZ) stem cells to produce more neural cells.
Strategies involving transplantation of these cells into the affected brain regions hold great promise; however, the exact mechanisms behind hNSCs’ success are not fully understood.
Neural stem cells are self-renewing and can differentiate into any type of neural cell, such as neurons and glial cells. With their ability to rescue dysfunctional neural pathways, NSCs are an ideal source for grafting and the development of novel therapies.
DURHAM, NC – A new study published this month in STEM CELLS Translational Medicine indicates that treating heart patients with mesenchymal stem cells (MSCs) does not increase their risk of irregular heart beat (arrhythmia). In fact, the MSCs had the opposite effect and showed promise of improving the condition.
“This could be an important breakthrough for many heart patients, as proarrhythmia – which is a new or more frequent occurrence of pre-existing arrhythmia – unfortunately can be a side effect of some of the drugs we’re using to treat these patients,” said the study’s lead author, Raul Mitrani, M.D., of the University of Miami School of Medicine’s Division of Cardiology (Miami, Florida).
DURHAM, NC - An infusion of a healthy donor’s unmodified stem cells might one day be used to prevent a type of osteoporosis caused by glucocorticoid therapy, according to a study published this month in STEM CELLS Translational Medicine. Osteoporosis is among the most significant side effects of glucocorticoid therapy, which is used for the management of inflammatory and auto-immune diseases.
DURHAM, NC - Researchers for the first time have shown how engineered stem cells can be used to deliver antibodies superior to those currently available for protecting against infectious diseases and biological warfare. The study appears in the August issue of STEM CELLS Translational Medicine.
DURHAM, NC - The medical world may be one step closer to an affordable, effective therapeutic vaccine for hepatitis C virus (HCV), according to a new study appearing in the latest issue of STEM CELLS Translational Medicine. The study, by scientists at Second Military Medical University in Shanghai, showed how exosomes secreted from umbilical mesenchymal stem cells (uMSC) efficiently suppressed HCV infection.
Chronic hepatitis C is a serious disease that can result in long-term health problems. Worldwide, 700,000 people die each year from HCV-related liver diseases, according to the World Health Organization. While newly developed antiviral medicines could cure approximately 90 percent of those with HCV infection, access to diagnosis and treatment is limited and there is currently no vaccine to prevent it.
DURHAM, NC - A new study published in STEM CELLS Translational Medicine (SCTM) by Badner et al shows how a minimally invasive stem cell treatment in rats can reduce secondary damage in traumatic spinal cord injury (SCI). While similar studies have also demonstrated the promise of stem cells as a therapy for SCI, what makes this one different is the type of stem cell used. For the first time, researchers evaluated whether a brain-derived stromal cell would be better suited to target the acute phase of SCI than cells derived from other tissue sources. The answer was yes.